PIP
KRYS icon

Palisades Investment Partners’s Krystal Biotech KRYS Stock Holding History

Palisades Investment Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.8M Buy
47,801
+2,396
+5% +$716K 5.05% 2
2026
Q1 		$11.7M Buy
45,405
+2,640
+6% +$702K 4.6% 2
2025
Q4 		$10.5M Buy
42,765
+1,376
+3% +$290K 3.98% 4
2025
Q3 		$7.31M Buy
41,389
+1,186
+3% +$178K 2.87% 10
2025
Q2 		$5.53M Sell
40,203
-493
-1% -$72.4K 2.42% 17
2025
Q1 		$7.34M Buy
40,696
+217
+0.5% +$36.5K 3.68% 8
2024
Q4 		$6.34M Buy
40,479
+3,436
+9% +$610K 2.68% 15
2024
Q3 		$6.74M Buy
37,043
+2,356
+7% +$454K 2.94% 14
2024
Q2 		$6.37M Buy
+34,687
New +$5.82M 3.15% 12

Other funds holding KRYS

Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Palisades Investment Partners's KRYS Position: Q2 2026 in Review

Palisades Investment Partners increased its Krystal Biotech (KRYS) stake by 5.3% in Q2 2026, buying an estimated $716K and bringing the position to 47,801 shares worth $17.8M. The position accounts for 5.05% of the portfolio, ranked #2.

Palisades Investment Partners first reported a position in KRYS in Q2 2024 and has held it in 9 quarters since. 144 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Palisades Investment Partners held 47,801 shares of Krystal Biotech worth $17.8M as of Q2 2026.
  • Palisades Investment Partners bought 2,396 Krystal Biotech shares in Q2 2026, an estimated $716K.
  • Krystal Biotech made up 5.05% of Palisades Investment Partners's portfolio in Q2 2026, its #2 holding.
  • Palisades Investment Partners first reported a position in Krystal Biotech in Q2 2024 and has held it in 9 quarters since.
  • 144 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Palisades Investment Partners's 13F filing for Q2 2026, filed 4 Aug 2026.